Welcome to the 2026 Annual General Meeting of Crescent Biopharma Inc's shareholders. I would like to introduce you to Joshua Brumm, Chief Executive Officer of Crescent Biopharma Inc, who will serve as the chair of this Annual General Meeting. Please go ahead.
Thank you. I am pleased to welcome you to Crescent Biopharma's 2026 Annual General Meeting of Shareholders. Your vote is important to us. If you haven't already done so, please vote at the indicated time during this meeting. On behalf of the Board of Directors and management, I would like to thank you for not only your participation in this meeting, but also your continued support. Before starting the meeting, I want to introduce you to the other members of our Board of Directors who are with us today. We have Peter Harwin, Chair of our Board of Directors, in addition to Alexandra Balcom, David Lubner, Susan Moran, and Jonathan Violin.
From our management team, we have Ellie Im, our Chief Medical Officer, Amy Reilly, our Chief Communications Officer, Barbara Bispham Hale, our General Counsel, Jonathan McNeill, our President and Chief Operating Officer, and Rick Scalzo, our Chief Financial Officer, joining us today. I would also like to introduce Ken Richardson from PricewaterhouseCoopers LLP, the company's independent registered public accounting firm, who's with us today and available to answer questions if any arise. Barbara will act as secretary of the meeting. The meeting is now officially called to order. When you joined today's virtual meeting, an agenda should have launched on your screen. Please note at the bottom of your screen are the rules of conduct for the meeting. To conduct an orderly meeting, we ask that participants abide by these rules. We will proceed with the formal business of the meeting as set forth in the proxy statement.
Our shareholders of record as of April 7th, 2026, or their duly authorized proxy holders are entitled to vote or submit questions during the meeting. You need not vote at this meeting if you have already voted by proxy. If you wish to change your vote or if you have not voted, you can vote or change your vote at any time once polls open and before the polls close. After the formal part of this meeting is concluded, we will answer any questions you may have as time permits. You may submit questions through the web portal. However, not all questions may be answered. If you wish to address the meeting, please submit your name and question through the designated field on the web portal. Please note that this meeting is being recorded.
However, no one attending via the webcast or telephone is permitted to use any audio or video recording device. Can Barbara please report at this time with respect to the mailing of the notice of the meeting?
I have an affidavit of mailing establishing that notice of the annual meeting was first distributed or made available on April 21, 2026, to all shareholders as of the close of business on April 7, 2026, and therefore declare that due notice has been given in accordance with the memorandum and articles of association of the company. The notice of the meeting and affidavit of mailing will be attached to the minutes of the meeting.
At this time, I would like to introduce Tracy Oates of Broadridge Financial Solutions, Inc. Ms. Oates has been appointed to act as Inspector of Election for this meeting. Her function is to decide upon the qualification of voters, accept their votes, and when balloting on all matters have been completed, to tally the final votes. Ms. Oates has taken and subscribed the company oath of office to execute her duties with strict impartiality. We will file this oath with the minutes of the meeting. I've been advised by the Inspector of Election that a quorum exists for the election of Jonathan Violin, and a quorum exists for the election of Susan Moran, and for the Proposals 2, 3, and 4. This meeting is therefore declared lawfully and properly convened, and will now proceed with the formal business of this annual meeting.
The time is now 9:03 A.M. Eastern Time on June 2, 2026, and the polls are now open for voting on all matters to be presented. Any shareholder who has not yet voted or wishes to change their vote may do so by clicking on the voting button on the web portal and by following the instructions there. Shareholders who have sent in proxies or voted by internet or telephone and do not want to change their vote do not need to take any further action.
This annual general meeting has been called to vote on the following proposals which are set out in detail in the notice and proxy material circulated to shareholders on April 21st, 2026. The first item of business is Proposal 1A, which seeks to approve the election of Jonathan Violin, PhD, as a Class II Director to serve for a three-year term expiring at the company's annual general meeting of shareholders to be held in 2029 or until a successor is duly elected and qualified, or until his earlier death, resignation, disqualification, or removal.
The second item of business is Proposal 1B, which seeks to approve the election of Susan Moran, MD, MSCE, as a Class II Director to serve for a three-year term expiring at the company's annual general meeting of shareholders to be held in 2029 or until her successor is duly elected and qualified, or until her earlier death, resignation, disqualification, or removal. Information regarding each of their qualifications is contained in the proxy statement. In accordance with the advance notice provision in the company's memorandum and articles of association, shareholders are required to provide advance notice of their intent to nominate candidates for directors. No other nominees were properly made in accordance with the articles. Therefore, I declare nominations to be closed. A motion to elect each of these directors is now in order.
The third item of business today is Proposal 2, which seeks to ratify the Audit Committee's appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31st, 2026. The fourth item of business is Proposal 3, which seeks the approval of a non-binding advisory basis of the compensation for our named executive officers. The fifth item of business is Proposal 4, which seeks the vote on a non-binding advisory basis of the frequency of future advisory votes to approve the compensation for our named executive officers. Each proposal is determined by poll. The company recommends that shareholders vote for each of the Proposals 1 through 3, and one year for Proposal 4.
We will now address any questions submitted from shareholders in accordance with the rules of conduct for the meeting. There are no questions related to the proposals at this time. We will now briefly pause for the submission of any final votes. The time is now 9:06 A.M. Eastern Time on June 2nd, 2026, and the polls are now closed for voting. The web portal is closed to questions.
Based on the preliminary report of the Inspector of Election, each of Jonathan Violin and Susan Moran has been elected to serve on the board until the annual general meeting to be held in 2029 or until her or his successor is duly elected and qualified, or until earlier of death, resignation, disqualification, or removal. The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31st, 2026, has been ratified by ordinary resolution. The compensation of our named executive officers has been approved on an advisory, non-binding basis by ordinary resolution. The frequency of future advisory votes on the compensation of our named executive officers has been approved on an advisory, non-binding basis as one year.
The final vote count will be included with the minutes of the meeting, and final results will be published in a current report on Form 8-K filed with the SEC within four business days of this meeting. There being no further business to be brought before this meeting, this concludes today's annual meeting. I would like to thank you all for attending and for your continued support of Crescent Biopharma.
This concludes today's meeting. Thank you for attending. You may now disconnect and have a wonderful rest of your day.